Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...

Racial disparities on incidence and survival in Kaposi sarcoma during the post-retroviral era: A Surveillance, Epidemiology and End Results program database (2000-2021) retrospective analysis. This is ...

Elemento is the director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Sternberg is the clinical director of the Englander Institute for Precision Medicine. Khozin is ...

Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...

A senior FDC official said the product is a “failed therapy” and confirmed that regulators have asked uniQure to run a new trial to prove the therapy actually helps Huntington’s patients. The ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...

Objective To examine the effects of strength training on patient-important outcomes of stroke recovery and to quantify the influence of the exercise prescription on treatment effects. Design ...

When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the industry.

Analysts downgraded uniQure N.V. after the U.S. Food and Drug Administration signalled it would require a sham surgery-controlled Phase 3 trial for the company’s Huntington’s disease therapy, dimming ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...